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Determining the Best Cerebrospinal 
Fluid Shunt Valve Design: The 
Pediatric Valve Design Trial 
Myriad cerebrospinal fluid shunt 
valve designs (lfe available (17, 18). 
None has eVer been shawn to be supe-
rior to another, ilHhough claims by neu-
rosurgeoLls and shunt manufacturers of 
the merits of particular designs arc nu-
merous. Such is the case with two recent 
shunt valve designs, the Orbis-Sigma 
valve (Cordis Corporation, Miami, FL) 
and the Delta valve (PS Medicat Co-
letta, CA). Both reduce the siphoning 
effect when the patient is in the upright 
position by different mecJlilnisTI1s. Re· ... 
ports of reduced complication f<ltes in 
uncontrolled series have been attributed 
to diminished shunt overdrainage (13, 
19,20, 22). 
Aside from the problems of interpret-
ing uncontrolled series, there are reasons 
why these shunts might be inferior to the 
standard differential pressure vlIlves, 
which h,we been used for morc than 3 
decades. The Orbis-Sigma valve is a high-
resistance system with a narrow orifice 
that might be easily occluded. The llexible 
membrane of the siphon control portion 
of the Delta valve may increase the Ven-
trictrlar pressure when the patient is in the 
upright position or become blocked by 
encasing scar Ussue (4, 6). Therefore, a 
randomized trial with a standard differ-
entia! pressure valvl" used as the control is 
required, to detennine efficacy. Such a 
trial has been commenced, with accntal of 
the necessary 345 patients nearly com-
pleted. Patients will be observed for a 
minimum of 1 year to determine whether 
any design provides a 50% reduction in 
fililure rllte, which is defined as shunt ob-
struction, loculated ventric1es, shunt 
overdrilin,lge, or shunt infection. The dl)... 
tails of the rationale and protocol for the 
mal will sub.sequently be published. 
Shunt valve designs 
Standard valves 
The origintll cerebrospinal fluid shunt 
valves were introduced 40 years ago 
(18). They operMe as differential pres-
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sure devices allowing one-way flow (10, 
23). When less than a threshold pressure 
difference across the valve, they remain 
closed, and when mOTe than the thresh-
old pressure djffen."nce~ they open (the 
opening pressure). There are a number 
of different valve mech.:mlsms, includ-
ing siliconQ ntbber slit valves, silicone 
rubber diaphragm valves, silicone rub-
ber miter valves, and metallic spring 
ball valves (5, 17). They all achieve es-
sentially the same pressure/flow char-
acteristics. A representative spring ball 
valve is shown in Figure 1. Once the 
valves are open, they' provide very little 
resjstaIlce to flow. When the patient is in 
the upright position, becallse of the col-
umn of water in the silunt and the ef-
fects of gravity, a large pressure differ-
ential exists between the head and the 
abdomen so that the shunt flows at a 
high rate until the pressure in the head 
is excessively negative (siphoning [2, 
11 D. This is the presumed explanation 
of the compliciltions llf shunt overdrain-
age, including subdural hematoma (12L 
slit ventricle syndrome (7, 14), cranioste-
nosis, and intracrania I hypotension (8). 
The standard valves usually arc sup-
plied by the milnuf<1ciurers as !ow-, me-
dium-, and high~pressure valves (and in 
Cordis Orbis-Sigma valve 
The Orbis-Sigma valve has quite dif-
ferent flOHr/pressure characteristics 
from those of a standard valve (20) (Fig. 
1). A flexible diaphragm moves along a 
piston of variable diameter, basically re-
sulting in three pressure/flow stages. In 
Stage 1, the valve functions in the same 
way as a standard differentiaL pressure 
diaphragm valve, with an opening pre.s-
Sllre and a low resistance to flow. In 
Stage 2, as the ventricular pressure in-
creilses, the diaphmgm descends along 
the piston~ whose diameter gets pro-
gressive larger. This reduces the flow 
orifice, dramatjcany increasing the resis-
tance to flow. This results in very little 
increase in flow rate despite a progres-
sive increase in pressure and effectively 
results in a flow limit. Stage 3 is a high-
pressure 'safety' release mechanism. 
When the pressure in the ventricular 
catheter reaches a high level, -40 em 
H::o.O, the diaphragm moves beyond the 
~nd of the piston, where the resistance is 
very low, resulting in a gush of fluid 
and limiting the pressure build lip. The 
transition between stages is not exact, so 
the pressure curve is sigmoid in shape 
(and thus the name Sigma). 
some cases, very 10\ .... ,- or very high-). PS J\,ledical Delta valve 
Unfortunately, there are no uniform The Delta valve is a standnrd valve 
standards for these designations, imd (silicone diaphragm mechanism) with 
the manner in whicb this pressure is an additional modified antisiphon de-
measured is also vari<lblc (5). In general, vice (13) (Fig, 1). The tlexiblc membrane 
the pressure designa tion refers to the of the siphon control portion moves 
opening pressure, either just at the be- against the orifice, increasing the res is-
ginning of flow or at a low flow rate, tance to flow, as the patient assumes the 
Stich as 5 ml per hour. Low, medium, upright posture and Siphoning starts to 
and high pressures in this scenario refer occur. This antisiphon effect reduces the 
to pressures of approximately 5, 10, and tendency to overdrainage in the upright 
15 cm of H20 pressure, respectively. position; however, the pressure rc-
Tile opening pressure differences are quired to maintain the same flow rate 
overwhelmed by the pressure effects actually slightly increases (Fig. 1). To 
when the patient aS5umes the upright properly function, the diaphragm must 
position, as discussed above. A number be freely mobile and the pressure out~ 
of series using different combinations of side the membrane must be atmospheric 
standard valve designs have reported (3). The position of the siphon control 
failure rates that (lfe very similar (1, 15, ,_device along the distal column of fluid is 
]6, 2'1). Therefore, cCI)1s1dering all stiln- ~ also important (9). The lower the device 
dard valves to be equivalent for the pur- is placed along the shunt path, rel<1tiv(> 
poses of the tri<ll seems to be reasonable. to tile ventricles, the greater the negcltive 
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Standard Differential Pressure Valve 
A 
Cordis Orbls Sigma Valve 
B 








FIGURE 1. Valve design and pressure/flow measurements for the three valves 
involved in the trial. A, standard differential pressure valve illustrated by the Cordis 
Hakim spring ball valve. The valve is either open or closed. Once open, the resistance 
to flow is very low, so there is very little pressure increase for increased flow rates, as 
shown in the pressure/flow curve. Accordingly, large flow rates are possible, as when 
(he patient assumes the upright position, leading to siphoning. H, Cordis Orbis-Sigma 
valve. As the flexible diaphragm moves along the increased diameter of the piston, the 
resistance rapidly increases, effectively producing a flow limit and reducing overdrain-
age. I f the pressure becomes too high, the diaphragm moves beyond the narrow por-
tion, which is a safety release mechanism. C, PS Medical Delta siphon control valve. 
Distal to the standard diaphragm valve is the siphon control portion. When the 
patient assumes the upright posilion and the pressure in the ventricle and shunt sys-
tem becomes negative, the membranes close on the orifice, increasing the resistance. 
The effects of this are shown in the accompanying graph, in which, with 50 cm H20 
of negative hydrostatic pressure (as by dropping the distal catheter tip 50 cm below 
the valve), (here is a slight increase in pressure at every flow rate. 
pressure that will occur in the vcntricles. 
In the limiting case, in which the device 
is placed at the level of the abdomen (or 
as in a lumbopcritoneal shunt), the si-
phon control portion would never be 
active and the valve would function ex-
actly like a differential pressure valve. 
The valve is available in three opening 
pressure levels (1, 15, and 2), which 
have sllccessively higher opening pres-
sures. The antisiphon portion functions 
in the same way. 
Shunt valve failure 
Several retrospective revie\\rs have 
shown remarkably similar failure rates for 
standard valves. In a combined series of 
1700 patients, the 1-year shunt failure rate 
was 409(J (21). A similar study from Port-
land, OR, had a 1-year failure rate of 359; 
(16). A prospective series comparing fron-
tal versus parietal shunt placement had a 
combined l-ycar failure rate of 30% 0). 
Failure rates after the 1st year have been 
much lower, averaging ~5t;k 
The Cordis Orbis-Sigmu valve has 
been reported to have a l-year failure 
rate of 20% (19), which is much lower 
than that of standard valves. Th~.rS 
fvledical Delt(l valve has also been re-
ported to have improved results (13). 
In 68 patients observed for 15 months 
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after Delta valve insertion, only nine 
valves had failed (W(llistedt, Karolin-
ska Institute, personal communicu-
Han). As these are uncontrolled series, 
the mechanism for the improved re-
sults is not known and confounding 
factors such as excellence of surgical 
technique pInyan unknown role. The 
cerebral ventricles nre maintained 
larger on avernge with the Cordis Or-
bis-Sigma valve than with standard 
valves. The proportion of slit, normal, 
und large ventricles with the Grbis-
Sigma valve was 8.2, 36.5, and 55.3 c/v, 
respectively, as compared with 30.9, 
21.3, and 47.8% with standard vnives 
(19). A higher number and proportion 
of proximClI obstructions occurred 
with the standard valves, suggesting 
that coaptation of the small ventricles 
and the ventricular catheter may pre-
dispose to plugging of the catheter 
holes with adjaccnt tissue. The propor-
ticm of valve failures was higher with 
the Cordis Grbis-Sigma valve, which 
was possibly related to the small ori-
fice, although the overnll failure rnte 
was much less. 
Trial design 
We designed the tri(li to detect a 50~~{, 
reduction in the l-year shunt failure rille 
(from 40 to 20%) comparing a standilrd 
shunt of the surgeon's choice, the Cor-
dis Orb is-Sigma valve, and the Delta 
valve. Patients newborn to 18 years of 
age undergoing their first ventriculn-
peritoneal shunt insertions are eligible 
and are randomized to receive one of 
the three valves at the time of surgery. 
The configuration of the equipment (i.e., 
one piece versus severn] pieces) or the 
technique (i.e., with the aid of i1 ven-
triculoscope) are decided by the indi-
vidual surgeon but arc recorded. Exclu-
sion criteria include prem{lture p<ltients 
'whose skin is too thin to accept any of 
the shunts, patients who have active in-
fections, patients 'with predisposition to 
shunt obstruction (blood-filled ventri-
cles), or patients with Dmlliy-Willker 
malformations. Patients will receive fol-
low-up for a minimum of 1 year. Shunt 
failure is subdivided into shunt obstruc-
tion, loculated ventricles, shunt over-
drainage, and shunt infection. Patients 
need to satisfy a series of clinical, radio-
logical, or surgical criteria to reach the 
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endpoint. All patients' eligibility and 
outcome will be reviewed by a blinded 
adjudication committee. The calculated 
sample size using an alpha type errQr of 
0.017 (0.05 divided by 3) and a beta type 
error of 0.2 (power, 80%) is 345 patients 
(115 per group). 
Trial limitations 
There are several obvious limita-
tions 'with this trial. It involves only 
pedi<ltric patients, and neither the sur-
geons nor the patients are blinded to 
the study protocol. A separate pediat-
ric tri.d is rCtlsonable given the specific 
diseases that Occur during this age. 
However, other adult trials to study 
normal-pressure hydrocephalus, for 
example, may be necessary. Blinding 
surgeons and pntients to the study 
protocol is impossible, given the 
readily identifiable characteristics of 
the shunt equipment before and <lfter 
implantation. Hmvever, there are speR 
cHic definitions in terms of clinical 
symptoms and signs und there are di-
agnostic tests for each subset of the 
primary outcome measure, shunt failR 
ure, which must be met. fn addition, 
an independent adjudication comR 
mittce blinded to shunt type wiJI deR 
termine 'whether each patient has 
reached the outcome measure. 
Likely benefits of the trial 
The results of this trial should allow 
surgeons to rationally choose a shunt 
design for use in their pediatric PJR 
tients. A reduction of 50% in the ] Ryear 
shunt failure rate ,,,,auld dramatically 
affect the lives of thousands of paR 
tients with shunts as well as create 
significant s<lvings for the health care 
system. Even a negative result \vould 
be helpful in thnt it would suggest thnt 
the most inexpensive shunt is adeR 
quate and that efforts should be fo-
cused in other areas, such as surgical 
technique, shunt material, etc. Finally, 
we think that this trial will establish a 
stand<lrd regarding clClims of imR 
proved efficacy for new shunt devices. 
These claims will need to be backed up 
by sound scientific evidence. 
Trial organization and progress 
The multicenter cerebrospinal fluid 
shunt design trial commenced patient ac-
cnml in October ]993. Patient accrual conR 
eluded in October ]995. TIle results of the 
trial should be available in the spring of 
]997. The primary authors of this commuR 
nication me the coprincipal investigators. 
The trial Data Center is in Vancouver, 
Canada. Participating centers and sur-
geons arc listed in the Appendix. 
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